Poster Abstract Session:
147. HIV: Switching Antiretrovirals
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Pediatric ID, HIV-STD-TB, Adult ID

Presentations:
Patient Willingness to Reduce Efavirenz Dose Based on Genetic Testing
Margaret Mitchell, - ; Caroline Wells, BS ; Xuechao Zhang, BS ; Joshua Hughes, MSN ; Je'purde White, PharmD ; Robertson Nash, MA, MBA, MSN ; David Haas, MD, FIDSA
Tolerability of Central Nervous System Symptoms among HIV-1 Infected Efavirenz Users: Analysis of Patient Electronic Medical Record Data
Lisa Rosenblatt, MD, MPH ; Michael S. Broder, MD, MSHS ; Tanya GK Bentley, PhD ; Eunice Chang, PhD ; Sheila Reddy, PhD, RPh ; Elya Papoyan, MPH ; Joel Myers, MPharm
Effect of Switching from Efavirenz to Rilpivirine in the Treatment of HIV-Infected Patients with Dyslipidemia
Pornpimol Laovachirasuwan, MD ; Ploenchan Chetchotisakd, MD ; Siriluck Anunnatsiri, MD ; Piroon Mootsikapun, MD
Posters
  • NVP OD.png (294.3 kB)
  • Virologic and Immunologic Outcomes of Nevirapine- and Efavirenz-Based Tenofovir Disoproxil Fumarate-Containing Regimens When Use As a Switch Therapy
    Angsana Phuphuakrat, MD, PhD ; Nutwipa Nakakul, MD ; Somnuek Sungkanuparph, MD ; Sasisopin Kiertiburanakul, MD, MHS
    Posters
  • TDF switching.pdf (991.9 kB)
  • Comparison of the Safety and Efficacy of Single and Multiple Tablet Regimens for Human Immunodeficiency Virus (HIV)
    Whitney Dickson, PharmD ; Andrew Merker, PharmD ; Tommy Chiampas, PharmD ; Rodrigo Burgos, PharmD ; Renata Smith, PharmD ; Melissa Badowski, PharmD
    Posters
  • IDSA STR MTR.pdf (451.6 kB)
  • A Study of the KNowledge And Beliefs Held by Patients Infected with HIV and Their HIV Health Care Providers Regarding Single Tablet Regimens (STR). (KNABSTR Study)
    Cynthia Frank, Ph.D. ; Tassos Kyriakides, PhD ; Audrey Omar, M.A. ; Gerald Friedland, MD, FIDSA ; Laurie Andrews, MPH ; Kathy Melbourne, PharmD, AAHIVP ; Michael J. Kozal, MD

    CME Credits:

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.